Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL26683264 | 0.98 | OPRM1 (0.39) | OPRM1OPRL1SMN1; SMN2CRBNCYP11B1 | |
| SCHEMBL340964 | 0.89 | OPRM1 (0.45) | OPRM1OPRL1SMN1; SMN2CRBNCYP11B1 | |
| SCHEMBL16600593 | 0.88 | CYP3A4 (0.38) | OPRM1OPRL1SMN1; SMN2CRBNCYP11B1 | |
| SCHEMBL27064690 | 0.88 | CYP3A4 (0.38) | OPRM1OPRL1SMN1; SMN2CRBNCYP11B1 | |
| SCHEMBL20758523 | 0.87 | CRBN (0.38) | OPRM1OPRL1SMN1; SMN2CRBNCYP11B1 | |
| Hydrochloric Acid SCHEMBL289271 | 0.87 | OPRM1 (0.44) | OPRM1OPRL1SMN1; SMN2CRBNCYP11B1 | |
| SCHEMBL20758273 | 0.84 | SMN1; SMN2 (0.35) | OPRM1OPRL1SMN1; SMN2CRBN | |
| SCHEMBL20669116 | 0.83 | OPRM1 (0.38) | OPRM1OPRL1SMN1; SMN2CRBNCYP11B1 | |
| SCHEMBL31580458 | 0.82 | OPRM1 (0.42) | OPRM1OPRL1SMN1; SMN2CRBNCYP11B1 | |
| SCHEMBL20941858 | 0.82 | OPRM1 (0.41) | OPRM1OPRL1SMN1; SMN2CRBNCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114591318-B | Pyrazolo heterocyclic compound, preparation method thereof, pharmaceutical composition and application | 中国医学科学院药物研究所 | 2024-06-21 | — | — | CN | claimed |
| CN-114507227-B | Benzisothiazole compound, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-06-21 | — | — | CN | claimed |
| CN-113135921-B | Dihydropyrimidine-spiro derivative and preparation method and application thereof | 山东大学 | 2022-06-17 | — | — | CN | claimed |
| CN-114591318-A | Pyrazolo heterocyclic compound, preparation method thereof, pharmaceutical composition and application | 中国医学科学院药物研究所 | 2022-06-07 | — | — | CN | claimed |
| WO-2022105782-A1 | BENZISOTHIAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国医学科学院药物研究所 | 2022-05-27 | — | — | WO | claimed |
| CN-114507227-A | Benzisothiazole compound, preparation method thereof, pharmaceutical composition and application | 中国医学科学院药物研究所 | 2022-05-17 | — | — | CN | claimed |
| CN-114507243-A | Isothiazole heterocyclic compound, preparation method thereof, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-05-17 | — | — | CN | claimed |
| EP-3765020-A1 | SPIROCYCLIC ROR-GAMMA MODULATORS | Escalier Biosciences B.V. (US) | 2021-01-20 | — | — | EP | claimed |
| WO-2019177997-A1 | SPIROCYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. (US) | 2019-09-19 | — | — | WO | claimed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4600247-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-25 | — | — | US | disclosed |
| WO-2017214367-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214367-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-7485647-B2 | 2-aminoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-03 | — | — | US | disclosed |
| US-20060287340-A1 | 2-Aminoquinoline derivatives | MSD K.K. (JP) | 2006-12-21 | — | — | US | disclosed |
| EP-1630162-A1 | 2-AMINOQUINOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287340-A1 | 2-Aminoquinoline derivatives | MCHR2, MC2R, MCHR1 | OPRM1 232/4885OPRL1 92/4885SMN1; SMN2 2295/4885 |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | OPRM1 1694/4885OPRL1 4024/4885SMN1; SMN2 3055/4885 |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | OPRM1 1694/4885OPRL1 4024/4885SMN1; SMN2 3055/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | OPRM1 140/4885OPRL1 434/4885SMN1; SMN2 3418/4885 |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | OPRM1 4736/4885OPRL1 4814/4885SMN1; SMN2 1680/4885 |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | OPRM1 1615/4885OPRL1 3646/4885SMN1; SMN2 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.